Related Experiment Video

Updated: Aug 14, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Serum uric acid and risk of coronary heart disease

S Goya Wannamethee1

  • 1Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, UK. goya@pcps.ucl.ac.uk

Current Pharmaceutical Design
|December 27, 2005
PubMed

Insights

Raised serum uric acid (SUA) is linked to cardiovascular disease (CVD) risk, but evidence suggests it

Area of Science:

  • Cardiovascular Epidemiology
  • Metabolic Syndrome Research

Background:

  • Epidemiological studies show a link between high serum uric acid (SUA) and increased risk of coronary heart disease (CHD) and cardiovascular disease (CVD).
  • The role of SUA as an independent risk factor for CHD is debated due to its association with established CVD risk factors like hypertension, dyslipidemia, and obesity.

Purpose of the Study:

  • To evaluate the independent role of serum uric acid (SUA) in the development of cardiovascular disease (CVD).
  • To assess whether lowering SUA levels through drug treatment impacts CVD outcomes.

Main Methods:

  • Review of large epidemiological studies and clinical trial data.
  • Analysis of associations between SUA levels and CVD incidence in diverse populations, including those with hypertension and pre-existing conditions.

Main Results:

  • SUA appears to be an independent predictor of CVD in hypertensive individuals and those with existing vascular disease, but not in healthy subjects.
  • The association of SUA with CHD in the general population may be explained by its correlation with other established risk factors.
  • Current evidence does not support a beneficial effect of drug-induced SUA lowering on CVD outcomes.

Conclusions:

  • There is limited support for an independent causal role of serum uric acid (SUA) in the development of coronary heart disease (CHD).
  • SUA may offer valuable prognostic information for patients with hypertension and established vascular disease.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...